Last reviewed · How we verify
Perindopril tablet
Perindopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.
Perindopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure. Used for Hypertension, Chronic heart failure, Stable coronary artery disease (secondary prevention).
At a glance
| Generic name | Perindopril tablet |
|---|---|
| Also known as | The test product, Coversyl 10 mg |
| Sponsor | Pharmtechnology LLC |
| Drug class | ACE inhibitor |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ACE inhibitors block the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation, reduced aldosterone secretion, and decreased sodium and water retention, resulting in lower blood pressure and reduced cardiac workload. The drug also has cardioprotective and renal-protective effects.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction
- Chronic kidney disease
Common side effects
- Dry cough
- Dizziness
- Hyperkalemia
- Headache
- Fatigue
- Angioedema
Key clinical trials
- Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) (NA)
- Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension. (PHASE3)
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia (PHASE3)
- Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy Volunteers (PHASE1)
- Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perindopril tablet CI brief — competitive landscape report
- Perindopril tablet updates RSS · CI watch RSS
- Pharmtechnology LLC portfolio CI